Shares of Curis, Inc. (NASDAQ:CRIS) rose 14% during mid-day trading on Thursday . The stock traded as high as $1.51 and last traded at $1.47. Approximately 743,681 shares changed hands during trading, an increase of 219% from the average daily volume of 233,342 shares. The stock had previously closed at $1.29.
CRIS has been the subject of several recent research reports. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research lowered shares of Curis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 15th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $13.17.
The company has a market capitalization of $44.37 million, a P/E ratio of -0.82 and a beta of 1.99. The company has a debt-to-equity ratio of 38.74, a quick ratio of 2.63 and a current ratio of 2.63.
COPYRIGHT VIOLATION WARNING: This story was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://weekherald.com/2019/03/14/curis-cris-stock-price-up-14.html.
About Curis (NASDAQ:CRIS)
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Read More: What is a Candlestick Chart?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.